Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Androbloc
- Development stage
- Unknown
- Lead developer
- G.L Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Androbloc is a nonsteroidal antiandrogen medication containing bicalutamide, developed and marketed by G.L Pharma. It works by competitively antagonizing the androgen receptor, thereby blocking the action of testosterone and other androgens that stimulate the growth of prostate cancer cells. Androbloc is primarily indicated for the treatment of advanced prostate cancer, often in combination with luteinizing hormone-releasing hormone (LHRH) analogues or surgical castration, and for locally advanced prostate cancer as monotherapy or adjuvant treatment. It is administered orally as film-coated tablets in 50 mg and 150 mg strengths.
- Brand names
- Androbloc
- Other names
- BicalutamidBicalutamide
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on Androbloc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Androbloc.